HomeBOSTON SCIENTIFIC

BOSTON SCIENTIFIC

LithoVue Empower™ Retrieval Deployment Device is Launched by Boston Scientific

9/21/18: “The LithoVue Empower Device is a unique tool that can improve ureteroscopic stone treatment as it puts the process of stone manipulation entirely into the hands of the surgeon,” said Dr. Brian Matlaga, the Stephens Professor of Urology at Johns Hopkins Medical Institutions and director of stone disease, James Buchanan Brady Urological Institute and presenting author of the data. “Ultimately, the LithoVue Empower Device introduces a novel efficiency into ureteroscopic stone surgery, as it makes it simpler for the urologist to pick up and move a stone – a historic source of frustration for this procedure."

Claret Medical to be Acquired by Boston Scientific

7/20/18: "Through the development and commercialization of the Sentinel System, Claret Medical has successfully introduced a new layer of safety and peace of mind for physicians and their patients undergoing TAVR procedures," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific.

Positive Late-Breaking Data From The INTREPID Study

4/24/18: This is the first and only prospective, double-blind, randomized, sham-controlled, multi-center study of deep brain stimulation (DBS) for advanced, levodopa-responsive Parkinson's disease (PD) in the United States.

OPTALYSE PE Long Term Results Reinforce Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

2/6/18: BTG plc (LSE: BTG) today highlighted OPTALYSE PE one year trial results, presented at the International Society on Endovascular Therapy in Florida. The findings confirm that bilateral pulmonary embolism patients treated in as little as 2 hours with a total tissue plasminogen activator (tPA) dose as low as 8mg continue to show improvements in RV/LV ratio over the long term with a very low all-cause mortality rate of 2%, an equally low recurrent PE rate of 2%, and continued quality of life improvements - further demonstrating the efficacy and safety of the OPTALYSE PE treatment regimens.

Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® Therapy Protocols for Pulmonary Embolism

12/14/17: BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study.

Boston Scientific Receives CE Mark for Vercise™ Gevia™ Deep Brain Stimulation System

  Industry's First MR-Conditional Directional DBS System with Stimulation Visualization Boston Scientific (NYSE: BSX) has received CE mark for the Vercise™ Gevia™ Deep Brain Stimulation (DBS) System*, a rechargeable, magnetic resonance (MR) conditional device indicated for the treatment of...

Lower Dose EKOS® Therapy For Pulmonary Embolism

  OPTALYSE PE included 101 patients with acute proximal PE at 17 centers randomized to one of four cohorts. All patients received therapeutic anticoagulation along with EKOSⓇ Acoustic Pulse Thrombolysis™ Therapy BTG plc (LSE: BTG), the global specialist healthcare...

Positive European Registry Results For WATCHMAN™ Left Atrial Appendage Closure Device

Largest Prospective Study of the WATCHMAN Device Presented as Late-Breaking Trial at Heart Rhythm 2017 Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION...